Novonesis reports 7% organic sales growth and 37.8% EBITDA margin in Q1 2026, confirming strong outlook.

Novonesis started 2026 with a robust 7% organic sales growth and an adjusted EBITDA margin of 37.8%, driven by growth in both Developed and Emerging markets. The company saw broad-based sales increases, including a 9% rise in Food & Health Biosolutions and 5% in Planetary Health Biosolutions, despite exiting certain countries. Adjusted net profit rose 8%, and free cash flow before acquisitions increased 9% to EUR 74 million. Novonesis confirmed its 2026 outlook, expecting 5-7% organic sales growth and a 37-38% adjusted EBITDA margin, supported by recent acquisitions and a successful bond issuance.